3,4-Dihydroimidazo[4,5-b]pyridin-5-one
≥95%
- Product Code: 175684
CAS:
28279-48-3
| Molecular Weight: | 135.12 g./mol | Molecular Formula: | C₆H₅N₃O |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD20037391 | |
| Melting Point: | Boiling Point: | 593.1±50.0°C at 760 mmHg | |
| Density: | Storage Condition: | Room temperature, dry seal |
Product Description:
Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. Its structure supports binding to enzyme active sites, making it valuable in designing drugs that target specific signaling pathways in tumor cells. Also employed in research for central nervous system agents due to its ability to cross the blood-brain barrier. Commonly found in medicinal chemistry workflows for optimizing lead compounds with improved potency and selectivity.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 250mg | 10-20 days | ฿22,580.00 |
+
-
|
3,4-Dihydroimidazo[4,5-b]pyridin-5-one
Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. Its structure supports binding to enzyme active sites, making it valuable in designing drugs that target specific signaling pathways in tumor cells. Also employed in research for central nervous system agents due to its ability to cross the blood-brain barrier. Commonly found in medicinal chemistry workflows for optimizing lead compounds with improved potency and selectivity.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :